This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Zao Ranbaxy, Russia
Zao Ranbaxy, a prominent player in the pharmaceutical industry, is headquartered in Russia (RU) and operates extensively across various regions. Founded in 1993, the company has established itself as a key provider of generic and branded medications, focusing on therapeutic areas such as cardiovascular, anti-infective, and gastrointestinal health. With a commitment to quality and innovation, Zao Ranbaxy offers a diverse portfolio of products that cater to the evolving needs of healthcare professionals and patients alike. The company has achieved significant milestones, including regulatory approvals and partnerships that enhance its market presence. Renowned for its rigorous quality standards and competitive pricing, Zao Ranbaxy continues to strengthen its position in the pharmaceutical landscape, contributing to improved health outcomes across Russia and beyond.
DitchCarbon Score
How does Zao Ranbaxy, Russia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zao Ranbaxy, Russia's score of 44 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zao Ranbaxy, based in Russia, currently does not report specific carbon emissions data, as indicated by the absence of available figures. The company is a current subsidiary of Sun Pharmaceutical Industries Limited, which may influence its climate strategies and reporting practices. As of now, Zao Ranbaxy has not established any documented reduction targets or climate pledges. This lack of specific commitments suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given its affiliation with Sun Pharmaceutical Industries Limited, emissions data and climate initiatives may be cascaded from this parent company. However, no specific emissions figures or reduction targets from Sun Pharmaceutical Industries Limited have been provided for Zao Ranbaxy at this time. In summary, Zao Ranbaxy's current climate commitments and emissions data remain unspecified, reflecting a potential area for future development in sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 77,616,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 377,728,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zao Ranbaxy, Russia is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
